First-of-its-kind study reveals predictive factors for outcomes of advanced stage AL amyloidosis
(WASHINGTON, August 15, 2023) – Early improvements in cardiac and hematologic parameters may predict better survival outcomes for patients being treated for stage IIIb AL amyloidosis, a deadly disease with a median survival of 4-6 months caused by abnormal protein buildup, according to new research released today in Blood Advances.
Amyloidosis occurs when normal proteins in the body misfold and form amyloid deposits in vital organs and tissues, which can lead to organ dysfunction, failure, and death. The prognosis for patients with advanced cardiac amyloidosis is extremely poor, ...












